MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dutertre, S.
Right arrow Articles by Prigent, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dutertre, S.
Right arrow Articles by Prigent, C.
Molecular Interventions 3:127-130 (2003)
© 2003 American Society of Pharmacology and Experimental Therapeutics

Viewpoint

Aurora-A Overexpression Leads to Override of the Microtubule-Kinetochore Attachment Checkpoint

Stéphanie Dutertre and Claude Prigent

Groupe Cycle Cellulaire, UMR6061 CNRS-Université de Rennes 1, Faculté de Médecine, 2 Avenue du Pr Léon Bernard CS 34317, 35043 Rennes cedex, France.

SUMMARY

The amplification of AURORA-A is frequently observed in specific epithelial cell malignancies. The overexpression of aurora-A, a Ser-Thr kinase known to localize to centrosomes during mitosis, appears to imbue cancerous cells with resistance to spindle-checkpoint-targeting drugs such as paclitaxel (Taxol). Indeed, a recent publication by Anand et al. indicates that overexpression of AURORA-A may interefere with spindle-microtubule attachment and disrupt the regulation of the spindle checkpoint by allowing cells with abnormal chromosomal separation to enter anaphase. Thus, the design of new drugs that specifically target aurora-A rather than other checkpoint proteins might alleviate the resistance to Taxol-like clinical therapeutics observed in some tumors.

The aurora proteins are kinases that belong to a recently characterized family first isolated in S. cerevisiae (1). Whereas yeasts possess only one aurora, the genomes of both C. elegans and D. melanogaster encode two auroras (aurora-A and -B), and mammalian genomes code for three (aurora-A, -B and -C) (2 –5). Aurora-A, a centrosome-localized mitotic kinase involved in spindle assembly and stability, phosphorylates proteins such as Eg5 (a kinesin-related protein) (6), TACC (transforming acidic coiled-coil protein) (7), and TPX2 (targeting protein for Xklp2) (8). In addition to being a substrate, TPX2 triggers the autophosphorylation (and activation) of aurora (9, 10).

The AURORA-A gene is located at chromosome position 20q13, a site frequently amplified in breast and colorectal tumors (11). Overexpression of aurora-A (together with aurora-B and -C) has been observed in many tumor cells. In addition, overexpressed aurora-A can transform Rat1 and NIH3T3 cells (12, 13). Several phenotypic and genotypic changes have been observed after aurora-A overexpression in culture cells: abnormal mitosis, polyploidy, centrosome amplification, and abrogation of the DNA damage-induced G2 checkpoint. In a recent paper, Anand and collaborators also reported that overexpression of aurora-A can override the mitotic checkpoint (14). But which of these events is involved for the appearance of the transformed phenotype? Most likely, all are necessary, although none is independently sufficient. Overexpression of active or inactive aurora-A always provokes aneuploidy and centrosome amplification, a phenotype observed in vivo in many tumor cells (12, 13, 15, 16), suggesting that the kinase activity of aurora-A is not essential for these effects. It was thought that both events might lead to genomic instability and tumorigenesis, and consequently, establish the early steps in the tumorigenesis process (17, 18). However, this phenotype alone is not sufficient to explain the oncogene potential of aurora-A because only the active kinase transforms cells.

In order to understand how aurora-A can transform cells, the efficiency of mitotic checkpoints has been analyzed in cells overexpressing the kinase. For instance, the inhibition of aurora-A by microinjection of aurora-A-specific antibodies into cells delays mitotic entry, whereas overexpression of aurora-A results in premature entry into mitosis in the presence of DNA damage induced by X-irradiation (19). These results suggest that aurora-A overexpression abrogates the DNA damage-induced G2 checkpoint. [This function has already been attributed to the single aurora in yeast (20). Until now it was thought that the mammalian aurora-B protein that localized at the kinetochore was the most likely aurora candidate for involvement in the spindle checkpoint (21).]

Now a new player has emerged to resolve the mystery. When the checkpoint is normally activated, cell cycle progression arrests in metaphase with Mad2 (mitotic arrest deficient 2) remaining localized at the unattached kinetochores. Anand and collaborators report that in cells overexpressing aurora-A, even with Mad2 decorating kinetochores, the metaphase arrest is not maintained (14) (Figure 1AGo). This result suggests that in the presence of an excess of aurora-A the activated mitotic checkpoint signalled by Mad2 is abrogated. Mad2 functions as an inhibitor of Cdc20, an activator of APC/C (anaphase promoting complex or cyclosome) that participates in the degradation of proteins and thereby triggers the metaphase-anaphase transition. The presence of Mad2 at any kinetochore during mitosis signals to the cell the presence of an unattached chromosome that precludes the metaphase-anaphase transition. As soon as the kinetochore is captured by microtubules, Mad2 dissociates from kinetochores; the inhibition of Cdc20 is relieved and APC/C becomes active. The data from Anand and collaborators suggest that aurora-A, when overexpressed, acts downstream of Mad2 and upstream of Cdc20 to override the mitotic checkpoint (Figure 1BGo). This is interesting because although aurora-A is degraded by the APC/C in a Cdh1-dependent manner, the kinase has previously been reported to associate with Cdc20 (16, 22, 23). Accordingly, the physiological signification of the Cdc20–Aurora-A association remains to be elucidated. Also, whether aurora-A phosphorylates Cdc20 remains unanswered.




View larger version (71K):
[in this window]
[in a new window]
  		Figure 1. Mad2 binding to kinetochores during metaphase-anaphase transition in HeLa cells. A. (Top)

In prophase every kinetochore is decorated with Mad2. Once a kinetochore is captured by microtubules, Mad2 labelling disappears. Metaphase-to-anaphase transition will be triggered only when all kinetochores are captured. However, any kinetochore remaining decorated with Mad2 (i.e., unattached chromosome) will activate the mitotic checkpoint leading to cell cycle arrest (Middle). In the presence of overexpressed aurora-A, the cell ignores the Mad2 signal and triggers metaphase exit (Bottom). B. Mad2 is an inhibitor of Cdc20, a known APC/C activator. Overexpression of aurora-A interferes with the Mad2–Cdc20 signal that promotes progression to anaphase (14).

 
Aurora-A is recognized as an oncogene because its kinase activity can transform NIH3T3 cells (13). Anand and collaborators choose to overexpress aurora-A in primary cell culture in order to assay its transformation potential. They were not able to transform the cell lines, indicating that aurora-A needs a particular background of abnormalities for its transformation activity to be revealed. Thus, research should be directed toward identifying the additional factors necessary for overexpressed aurora-A to trigger cell transformation. In fact, this was already implied by the observation that only two cell lines have been successfully transformed by aurora-A overexpression (12, 13). Anand and collaborators also report that, compared to chromosomes in immortalized cells, the chromosomes in primary cells expressing catalytically inactive aurora do not become polyploid (Figure 2Go) (14). However, whether overexpression of inactive aurora-A also results in mitotic checkpoint override has yet to be elucidated.



View larger version (23K):
[in this window]
[in a new window]
  		Figure 2. Effect of overexpression of various forms of aurora-A in different cell lines. A. Overexpression of active aurora-A in immortalized or primary cells leads to polyploidy and centrosome amplification. B. Overexpression of inactive aurora-A in primary cells does not lead to polyploidy and centrosome amplification. C. Overexpression of active, hyperactive, or nondegradable aurora-A transforms immortalized cells but not primary cells. Associated references in parentheses.

 
Anand et al. also report that whereas HeLa cells treated with taxol arrest in metaphase and eventually die by apoptosis, HeLa cells overexpressing aurora-A become resistant to apoptosis. This compelling result should have an extremely important impact: taxol is a drug currently used in several chemotherapeutic cancer protocols and aurora-A is overexpressed in cells from various tumors. Several clinicians have already noticed that in some cases lowering taxol in chemotherapy increases the efficiency of the cancer cure.


Stéphanie Dutertre, PhD, is currently a postdoctoral fellow with Claude Prigent at the UMR6061 Genetics and Development in the University of Rennes 1, France. She is working on the relationship between aurora-A and oncogenesis. She is a fellow of the ARC (Association pour la Recherche sur le Cancer). Previously, her doctoral studies with Mounira Amor-Gueret focused on the function and regulation of the helicase BLM, mutated in Bloom syndrome. Email stephanie.dutertre{at}univ-rennes1.fr


Claude Prigent, PhD, is Director of Research at the CNRS (Centre National de la Recherche Scientifique), and head of the Cell Cycle Group, at the UMR6061 Genetics and Development, in the University of Rennes 1, France. Address correspondence to CP. Email: claude.prigent{at}univ-rennes1.fr

ACKNOWLEDGMENTS

Dr. Prigent’s research is financed by the "Ligue Nationale Contre le Cancer" (équipe labellisée).

References

  1. Chan, C.S. and Botstein, D. Isolation and characterization of chromosome-gain and increase-in-ploidy mutants in yeast. Genetics 135, 677–691 (1993).[Abstract]
  2. Giet, R. and Prigent, C. Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. J. Cell Sci. 112, 3591–3601 (1999).[Abstract]
  3. Adams, R.R., Carmena, M., and Earnshaw, W.C. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 11, 49–54 (2001).[CrossRef][Medline]
  4. Bischoff, J.R. and Plowman, G.D. The Aurora/Ipl1p kinase family: Regulators of chromosome segregation and cytokinesis. Trends Cell Biol 9, 454–459 (1999).[CrossRef][Medline]
  5. Nigg, E.A. Mitotic kinases as regulators of cell division and its checkpoint. Nature Rev. Mol. Cell. Biol. 2, 21–32 (2001).[CrossRef][Medline]
  6. Giet, R., Uzbekov, R., Cubizolles, F., Le Guellec, K., and Prigent, C. The Xenopus laevis aurora-related protein kinase pEg2 associates with and phosphorylates the kinesin-related protein XlEg5. J. Biol. Chem. 274, 15005–15013 (1999).
    The first aurora-A substrate identified was the microtubule based motor protein Eg5.[Abstract/Free Full Text]
  7. Giet, R., McLean, D., Descamps, S., Lee, M.J., Raff, J.W., Prigent, C., and Glover, D.M. Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J. Cell Biol. 156, 437–451 (2002).
    TACC is an aurora-A substrate that needs to be phosphorylated in order to localize to the pole of the spindle.[Abstract/Free Full Text]
  8. Kufer, T.A., Sillje, H.H., Korner, R., Gruss, O.J., Meraldi, P., and Nigg, E.A. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J. Cell Biol. 158, 617–623 (2002).
    TPX2 is an aurora-A substrate that localises aurora-A to the spindle poles.[Abstract/Free Full Text]
  9. Tsai, M.Y., Wiese, C., Cao, K., Martin, O., Donovan, P., Ruderman, J., Prigent, C., and Zheng, Y. A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nat. Cell Biol. 15, 242–248 (2003).
    Aurora-A is activated by autophosphorylation when it binds to TPX2.
  10. Eyers, P.A., Erikson, E., Chen, L.G., and Maller, J.L. a novel mechanism for activation of the protein kinase aurora-A. Curr. Biol. (in press) (2003).
  11. Sen, S., Zhou, H., and White, R.A. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14, 2195–2200 (1997).[CrossRef][Medline]
  12. Bischoff, J.R., Anderson, L., Zhu, Y. et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17, 3052–3065 (1998).
    The first data demonstrating that aurora-A behaves as an oncogene when overexpressed.[CrossRef][Medline]
  13. Zhou, H., Kuang, J., Zhong, L., Kuo, W.L., Gray, J.W., Sahin, A., Brinkley, B.R., and Sen, S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 20, 189–193 (1998).[CrossRef][Medline]
  14. Anand, S., Penrhyn-Lowe, S., and Venkitaraman, A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3, 51–62 (2003).
    Taxol treatment induces genetic instability in cells overexpressing aurora-A.[CrossRef][Medline]
  15. Meraldi, P., Honda, R., and Nigg, E.A. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J. 21, 483–492 (2002).
    Polyploidy and centrosome amplification observed upon aurora-A overexpression is due to a defect in cytokinesis.[CrossRef][Medline]
  16. Littlepage, L.E., and Ruderman, J.V. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev. 16, 2274–2285 (2002).
    A new degradation box targets aurora-A to be degraded by the APC/C in a Cdh1 dependent pathway.[Abstract/Free Full Text]
  17. Miyoshi, Y., Iwao, K., Egawa, C., and Noguchi, S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer 92, 370–373 (2001).[CrossRef][Medline]
  18. Goepfert, T.M., Adigun, Y.E., Zhong, L., Gay, J., Medina, D., and Brinkley, W.R. Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res. 62, 4115–4122 (2002).[Abstract/Free Full Text]
  19. Marumoto, T., Hirota, T., Morisaki, T. et al. Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 7, 1173–1182 (2002).[Abstract]
  20. Biggins, S. and Murray, A.W. The budding yeast protein kinase Ipl1/Aurora allows the absence of tension to activate the spindle checkpoint. Genes Dev. 15, 3118–3129 (2001).[Abstract/Free Full Text]
  21. Kallio, M.J., McCleland, M.L., Stukenberg, P.T., and Gorbsky, G.J. Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Curr. Biol. 12, 900–905 (2002).[CrossRef][Medline]
  22. Farruggio, D.C., Townsley, F.M., and Ruderman, J.V. Cdc20 associates with the kinase aurora2/Aik. Pro.c Natl. Acad. Sci. U.S.A. 96, 7306–7311 (1999).[Abstract/Free Full Text]
  23. Castro, A., Vigneron, S., Bernis, C., Labbe, J.C., Prigent, C., and Lorca, T. (The D-Box-activating domain (DAD) is a new proteolysis signal that stimulates the silent D-Box sequence of Aurora-A. EMBO Rep 3, 1209–1214 2002).
    Complete sequence of a the "degradation box activating domain" that target aurora-A to be degraded by APC/C.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
I. Perez de Castro, G. de Carcer, and M. Malumbres
A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy
Carcinogenesis, May 1, 2007; 28(5): 899 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Tanaka, Y. Hashimoto, T. Ito, K. Kondo, M. Higashiyama, S. Tsunoda, C. Ortiz, Y. Sakai, J. Inazawa, and Y. Shimada
The Suppression of Aurora-A/STK15/BTAK Expression Enhances Chemosensitivity to Docetaxel in Human Esophageal Squamous Cell Carcinoma
Clin. Cancer Res., February 15, 2007; 13(4): 1331 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Reiter, P. Gais, U. Jutting, M. K. Steuer-Vogt, A. Pickhard, K. Bink, S. Rauser, S. Lassmann, H. Hofler, M. Werner, et al.
Aurora Kinase A Messenger RNA Overexpression Is Correlated with Tumor Progression and Shortened Survival in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., September 1, 2006; 12(17): 5136 - 5141.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
N. Keen
Aurora Kinases and Cancer Therapy
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 178 - 181.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Tanaka, Y. Hashimoto, T. Ito, T. Okumura, T. Kan, G. Watanabe, M. Imamura, J. Inazawa, and Y. Shimada
The Clinical Significance of Aurora-A/STK15/BTAK Expression in Human Esophageal Squamous Cell Carcinoma
Clin. Cancer Res., March 1, 2005; 11(5): 1827 - 1834.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dutertre, S.
Right arrow Articles by Prigent, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dutertre, S.
Right arrow Articles by Prigent, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.